Appendix Table D31. Randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults (continued)

Appendix Table D31. Randomized controlled clinical trials that examined efficacy of propranolol for migraine prevention in adults

Reference
Total Sample Size as Randomized
% Women / Aim / Definition of Migraine / Duration of Migraine, Years / Age of Subjects / Baseline Severity /
Diamond, 197650
Sample 83
80.7% women / To evaluate propranolol in the prophylaxis of migraine / Classic or common migraine (Ad Hoc Committee) / Not reported / Mean: 38.1 / Not reported
Stensrud, 197651
Stensrud, 197651
Sample 20
70% women / To investigate the effects of propranolol in the racemic form (Inderal) and d-propranolol. / Common and classic migraine (as defined by the Ad Hoc Committee) / Not reported / 43.5 / Not reported
Forssman, 197652
Sample 40
87.5% women / To compare the preventive effect of propranolol on migraine attacks with placebo in a double-blind crossover trial / Not reported / 18.9 / Mean: 37.4 / Not reported
Pradalier, 198953
Sample 55
76% women / To evaluate the efficacy and tolerability of long-acting propranolol in migraine / International Headache Society / Not reported / Mean: 37.4 / Mean frequency of migraine (month): 4
Nadelman, 198654
Sample 57
85.5% women / To compare the relative efficacy and safety of propranolol with that of placebo in the prophylaxis of migraine headache / Classic and/or common migraine headaches as set forth by the Ad Hoc Committee on the Classification of Headache / 1-5: 22.6%; 6-10: 27.4%; 11-15: 14.5%; 16-20: 9.7%; 21-25: 8.1%; 26+: 17.7% / Not reported / Headache Unit Index: 1.09
Sargent, 198555
Sample 149
79% women / To evaluate the prophylactic effect and tolerance of naproxen sodium compared to propranolol hydrochloride and placebo in migraine / Common or classical migraine, or a combination migraine and muscle contraction headache (no definition provided) / 20 / Mean: 30 / Not reported
Ahuja, 198556
Sample 26
46.2% women / To compare the effectiveness of a selective and a non-selective beta1-receptor antagonist i.e. atenolol (Tenormin) and propranolol (Inderal), in the prophylaxis of migraine / Ad Hoc Committee on Classification of Headache (1962) / Not reported / Not reported / Not reported
Malvea, 197357
Sample 31
87% women / To determine the relative effectiveness of propranolol in the prevention of migraine as compared to a placebo in a double-blind trial / Not reported / Not reported / Not reported (ranges: 25-57) / Average headache units: 25.4 (no definition provided)
Wideroe, 197458
Sample 30
86.7% women / To investigate the value of propranolol in preventing attacks of migraine / Classic or common migraine (Ad Hoc Committee, 1962) / Not reported / Mean: 40 / All except four patients had two or more attacks a month
Palferman, 198359
Sample 36
80% women / To assess the efficacy of prophylactic propranolol on the severity and frequency of their symptoms / Episodic headache with other accepted disorders of cerebral function including visual disturbances and vomiting / 17.5 (all patients: 11.3) / Mean: 41.4 (all patients: 37.8) / Not reported
Tfelt-Hansen, 198460
Sample 96
74% women / To compare the beta-adrenergic blocker timolol to an established drug, propranolol, and to placebo for prophylactic effect in common migraine / Between 2 and 6 common migraine attacks per month as defined by the ad hoc committee and by Olsen / 20.9 / Mean: 39.5 / Number of migraine attacks per 4 weeks: 5.7
Standnes, 198261
Sample 25
80% women / To evaluate the prophylactic effect of timolol in migraine / Common migraine attacks (as defined by the Ad Hoc Committee) / Not reported / Mean: 41.4 / Mean number of attacks (4 weeks): 6.65
Stensrud, 198062
Sample 35
68.6% women / To compare the effectiveness of a selective and a non-selective beta1-receptor antagonist i.e. atenolol (Tenormin) and propranolol (Inderal), in the prophylaxis of migraine / Ad Hoc Committee on Classification of Headache (1962) / Not reported / Not reported / Not reported
al-Qassab, 199363
Sample 45
80% women / To assess the effectiveness of two different doses of a long-acting formulation of propranolol (propranolol LA) in patients with severe migraine / Diagnosis of migraine was made on clinical assessment. / Median: 9 / Median: 36 / Median attacks (month): 4
Diener, 200443
Sample 575
79.8% women / To evaluate the efficacy and safety of two doses of topiramate and safety of two doses of topiramate vs. placebo for migraine prophylaxis, with propranolol (PROP) as an active control / International Headache Society / Not reported / Median: 41 / Mean monthly migraine frequency: 5.1
Rafieian-Kopaei, 200564
Sample 105
% women Not reported / To compare the prophylactic activity of propranolol and amitriptyline on frequency, duration and severity of migraine attacks / Migraine (International Headache Society) / >1 (from inclusion criteria) / Not reported / Mean attack frequency: 4.02 (per month)
Weber, 197265
Sample 25
52% women / To compare the prophylactic effect of the propranolol to placebo / Migraine (Classification of headache, JAMA (1962) 179, 717) / Not reported / Mean: 40.6 / Not reported
Pradalier, 198966
Sample 55
75.7% women / To assess the efficacy and safety of long-acting propranolol (LA. P) 160 mg once-daily in the prophylactic treatment of migraine / Migraine (International Headache Society) / Not reported / Not reported / Not reported
Kuritzky, 198767
Sample 38
% women Not reported / 1) To evaluate the efficacy of long acting propranolol (Deralin SR) in reducing the frequency, duration and severity of migraine when compared with placebo, 2) To register possible side effects, and 3) to study correlation between plasma propranolol levels and clinical effectiveness in migraine. / Not reported (While eligibility criteria are not reported, author described "classic or common migraine" patients were included.) / 14.2 / Not reported / Mean number of migraine attacks: 3 (“"All patients averaged at least 3 attacks per month when untreated.")

D-131